Compare Recursion Pharmaceuticals Inc (RXRX) vs Essential Utilities Inc. Common Stock (WTRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Essential Utilities Inc. Common Stock — how do they compare? Recursion Pharmaceuticals Inc trades at $3.67 (market cap $2.08B), while Essential Utilities Inc. Common Stock trades at $39.82 (market cap $11.15B). The key difference: Essential Utilities Inc. Common Stock is far larger — about 5.4× Recursion Pharmaceuticals Inc's market cap, and Essential Utilities Inc. Common Stock pays a 3.67% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Essential Utilities Inc. Common Stock for 0 Days on average.
| RXRX | WTRG | |
|---|---|---|
Market Cap | $2.08B | $11.15B |
Volume | 19,700,033 | 1,760,234 |
Sector | Health | Utilities |
52-Week High | $6.79 | $42.00 |
52-Week Low | $2.84 | $36.25 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $1.60B | $19.66B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported revenue of $74.26M in 2025 but posted a significant net loss of -$644.76M, reflecting negative profit margins. Recent news highlights strategic AI partnerships and pipeline expansion, though the stock faces high short interest and ongoing operational losses.
Outlook remains speculative with 40% analyst buy ratings but substantial financial losses. Key opportunities include AI-driven drug discovery partnerships, while risks involve cash burn, competitive pressures, and delayed profitability. The stock's valuation at 36.1x sales appears stretched given current financial performance.
WTRG trades at $39.29, up 0.36% with neutral technical signals. The stock shows mixed earnings performance with two beats and one miss in recent quarters, while maintaining strong profitability margins (21.6% net income margin). Analyst consensus is bullish with a $44.50 price target, supported by ongoing acquisitions and pending merger developments with American Water.
The stock presents a stable utility investment with moderate growth potential through strategic acquisitions, though near-term earnings volatility and integration risks from the pending merger warrant caution. Current valuation at 20.15 P/E appears reasonable given the company's consistent cash flow generation and defensive sector positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Essential Utilities Inc. Common Stock
Essential Utilities Inc. is a holding company for regulated water, wastewater, and natural gas utilities, operating under the Aqua and Peoples brands. It serves customers across Pennsylvania, Ohio, Texas, Illinois, North Carolina, New Jersey, Indiana, Virginia, and Kentucky.
Read more on WTRG →
